References
1.
Bishop AE, Polak JM, Facer P, et al: Neuron specific enolase: a common marker for the endocrine cells and innervation of the gut and pancreas. Gastroenterology 1982;83:902–915.
2.
Lloyd RV, Wilson BS: Specific endocrine tissue marker defined by a monoclonal antibody. Science 1983;222:628–630.
3.
Rode J, Dhillon AP, Doran JF, et al: PGP 9.5, a new marker for human neuroendocrine tumors. Histopathology 1985;9:147–158.
4.
Wiedenmann B, Franke WW, Kuhn C, et al: Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci USA 1986;83:3500–3504.
5.
Klimstra DP, Öberg K, Komminoth P, Bordi C: Non-Functioning Tumors and Microadenomas. Lyon, IARC Press, 2004.
6.
Klimstra DS PA, Öberg K, Komminoth P, Bordi C: Non-Functioning Tumors and Microadenomas. Lyon, IARC Press, 2004.
7.
Marion-Audibert AM, Barel C, Gouysse G, et al: Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 2003;125:1094–1104.
8.
Kimura W, Kuroda A, Morioka Y: Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci 1991;36:933–942.
9.
Barakat MT, Meeran K, Bloom SR: Neuroendocrine tumors. Endocr Relat Cancer 2004;11:1–18.
10.
Mignon M: Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000;62(suppl 1):51–58.
11.
Broder LE, Carter SK: Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann Intern Med 1973;79:101–107.
12.
Broughan TA, Leslie JD, Soto JM, Hermann RE: Pancreatic islet cell tumors. Surgery 1986;99:671–678.
13.
Dial PF, Braasch JW, Rossi RL, et al: Management of nonfunctioning islet cell tumors of the pancreas. Surg Clin N Am 1985;65:291–299.
14.
Grama D, Skogseid B, Wilander E, et al: Pancreatic tumors in multiple endocrine neoplasia type 1: clinical presentation and surgical treatment. World J Surg 1992;16:611–618; discussion 618–619.
15.
Kloppel G, Heitz PU: Pancreatic endocrine tumors. Pathol Res Pract 1988;183:155–168.
16.
Legaspi A, Brennan MF: Management of islet cell carcinoma. Surgery 1988;104:1018–1023.
17.
Solcia ESF, Rindi G, Bonato M, Capella C: Pancreatic Endocrine Tumors: General Concepts; Non-Functioning Tumors and Tumors with Uncommon Function. Boca Raton, CRC Press, 1991.
18.
Couvelard A, O’Toole D, Turley H, et al: Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumors: negative correlation of microvascular density and VEGF expression with tumor progression. Br J Cancer 2005;92:94–101.
19.
Pape UF, Bohmig M, Berndt U, et al: Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a German referral center. Ann NY Acad Sci 2004;1014:222–233.
20.
Corleto VD, Panzuto F, Falconi M, et al: Digestive neuroendocrine tumors: diagnosis and treatment in Italy. A survey by the Oncology Study Section of the Italian Society of Gastroenterology (SIGE). Dig Liver Dis 2001;33:217–221.
21.
Cheslyn-Curtis S, Sitaram V, Williamson RC: Management of non-functioning neuroendocrine tumors of the pancreas. Br J Surg 1993;80:625–627.
22.
Madura JA, Cummings OW, Wiebke EA, et al: Nonfunctioning islet cell tumors of the pancreas: a difficult diagnosis but one worth the effort. Am Surg 1997;63:573–577; discussion 577–578.
23.
Matthews BD, Heniford BT, Reardon PR, et al: Surgical experience with nonfunctioning neuroendocrine tumors of the pancreas. Am Surg 2000;66:1116–1122; discussion 1122–1123.
24.
White TJ, Edney JA, Thompson JS, et al: Is there a prognostic difference between functional and nonfunctional islet cell tumors? Am J Surg 1994;168:627–629; discussion 629–630.
25.
Chu QD, Hill HC, Douglass HO Jr, et al: Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas. Ann Surg Oncol 2002;9:855–862.
26.
Pereira PL, Wiskirchen J: Morphological and functional investigations of neuroendocrine tumors of the pancreas. Eur Radiol 2003;13:2133–2146.
27.
La Rosa S, Sessa F, Capella C, et al: Prognostic criteria in nonfunctioning pancreatic endocrine tumors. Virchows Arch 1996;429:323–333.
28.
Eriksson B, Oberg K: An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993;32:203–208.
29.
Eriksson B, Skogseid B, Lundqvist G, et al: Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer 1990;65:1883–1890.
30.
Que FG, Sarmiento JM, Nagorney DM: Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. Cancer Control 2002;9:67–79.
31.
Skogseid B, Oberg K, Akerstrom G, et al: Limited tumor involvement found at multiple endocrine neoplasia type I pancreatic exploration: can it be predicted by preoperative tumor localization? World J Surg 1998;22:673–677; discussion 667–668.
32.
Thomas-Marques L, Murat A, Delemer B, et al: Prospective endoscopic ultrasonographic evaluation of the frequency of nonfunctioning pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. Am J Gastroenterol 2006;101:266–273.
33.
Binkovitz LA, Johnson CD, Stephens DH: Islet cell tumors in von Hippel-Lindau disease: increased prevalence and relationship to the multiple endocrine neoplasias. Am J Roentgenol 1990;155:501–505.
34.
Curley SA, Lott ST, Luca JW, et al: Surgical decision-making affected by clinical and genetic screening of a novel kindred with von Hippel-Lindau disease and pancreatic islet cell tumors. Ann Surg 1998;227:229–235.
35.
Hough DM, Stephens DH, Johnson CD, Binkovitz LA: Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. AJR Am J Roentgenol 1994;162:1091–1094.
36.
Neumann HP, Dinkel E, Brambs H, et al: Pancreatic lesions in the von Hippel-Lindau syndrome. Gastroenterology 1991;101:465–471.
37.
Verhoef S, van Diemen-Steenvoorde R, Akkersdijk WL, et al: Malignant pancreatic tumor within the spectrum of tuberous sclerosis complex in childhood. Eur J Pediatr 1999;158:284–287.
38.
Francalanci P, Diomedi-Camassei F, Purificato C, et al: Malignant pancreatic endocrine tumor in a child with tuberous sclerosis. Am J Surg Pathol 2003;27:1386–1389.
39.
Lebtahi R, Cadiot G, Sarda L, et al: Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997;38:853–858.
40.
Krenning EP, Kwekkeboom DJ, Bakker WH, et al: Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716–731.
41.
Ricke J, Klose KJ: Imaging procedures in neuroendocrine tumors. Digestion 2000;62(suppl 1):39–44.
42.
Ricke J, Klose KJ, Mignon M, et al: Standardisation of imaging in neuroendocrine tumors: results of a European Delphi process. Eur J Radiol 2001;37:8–17.
43.
Froidevaux S, Eberle AN, Christe M, et al: Neuroendocrine tumor targeting: study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model. Int J Cancer 2002;98:930–937.
44.
Henze M, Schuhmacher J, Dimitrakopoulou-Strauss A, et al: Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumor, visualised with (68)Ga-DOTATOC PET. Eur J Nucl Med Mol Imaging 2004;31:466.
45.
Ugur O, Kothari PJ, Finn RD, et al: Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 2002;29:147–157.
46.
Rubello D, Rufini V, Casara D, et al: Clinical role of positron emission tomography (PET) in endocrine tumors. Panminerva Med 2002;44:185–196.
47.
Bombardieri E, Seregni E, Villano C, et al: Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging 2004;48:150–163.
48.
Buetow PC, Miller DL, Parrino TV, Buck JL: Islet cell tumors of the pancreas: clinical, radiologic, and pathologic correlation in diagnosis and localization. Radiographics 1997;17:453–472; quiz 472A–472B.
49.
Fidler JL, Johnson CD: Imaging of neuroendocrine tumors of the pancreas. Int J Gastrointest Cancer 2001;30:73–85.
50.
Kalra MK, Maher MM, Mueller PR, Saini S: State-of-the-art imaging of pancreatic neoplasms. Br J Radiol 2003;76:857–865.
51.
Rappeport ED, Hansen CP, Kjaer A, Knigge U: Multidetector computed tomography and neuroendocrine pancreaticoduodenal tumors. Acta Radiol 2006;47:248–256.
52.
Procacci C, Carbognin G, Accordini S, et al: Nonfunctioning endocrine tumors of the pancreas: possibilities of spiral CT characterization. Eur Radiol 2001;11:1175–1183.
53.
Nino-Murcia M, Tamm EP, Charnsangavej C, Jeffrey RB Jr: Multidetector-row helical CT and advanced postprocessing techniques for the evaluation of pancreatic neoplasms. Abdom Imaging 2003;28:366–377.
54.
Tamm EP, Silverman PM, Charnsangavej C, Evans DB: Diagnosis, staging, and surveillance of pancreatic cancer. AJR Am J Roentgenol 2003;180:1311–1323.
55.
Semelka RC, Custodio CM, Cem Balci N, Woosley JT: Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI. J Magn Reson Imaging 2000;11:141–148.
56.
Owen NJ, Sohaib SA, Peppercorn PD, et al: MRI of pancreatic neuroendocrine tumors. Br J Radiol 2001;74:968–973.
57.
Fuhrman GM, Charnsangavej C, Abbruzzese JL, et al: Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 1994;167:104–111; discussion 111–113.
58.
Van Hoe L, Gryspeerdt S, Marchal G, et al: Helical CT for the preoperative localization of islet cell tumors of the pancreas: value of arterial and parenchymal phase images. AJR Am J Roentgenol 1995;165:1437–1439.
59.
Brown R, Scoggins C, Tamm E, et al: Intrapancreatic accessory spleen masquerading as pancreatic neuroendocrine tumor. Surg Rounds 2004;27:310–315.
60.
Noone TC, Hosey J, Firat Z, Semelka RC: Imaging and localization of islet-cell tumors of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab 2005;19:195–211.
61.
Rickes S, Unkrodt K, Ocran K, et al: Differentiation of neuroendocrine tumors from other pancreatic lesions by echo-enhanced power Doppler sonography and somatostatin receptor scintigraphy. Pancreas 2003;26:76–81.
62.
Rosch T, Lightdale CJ, Botet JF, et al: Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992;326:1721–1726.
63.
Zimmer T, Scherubl H, Faiss S, et al: Endoscopic ultrasonography of neuroendocrine tumors. Digestion 2000;62(suppl 1):45–50.
64.
Kann P, Bittinger F, Engelbach M, et al: Endosonography of insulin-secreting and clinically non-functioning neuroendocrine tumors of the pancreas: criteria for benignancy and malignancy. Eur J Med Res 2001;6:385–390.
65.
Ichikawa T, Peterson MS, Federle MP, et al: Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 2000;216:163–171.
66.
Eriksson B, Arnberg H, Lindgren PG, et al: Neuroendocrine pancreatic tumors: clinical presentation, biochemical and histopathological findings in 84 patients. J Intern Med 1990;228:103–113.
67.
Stivanello M, Berruti A, Torta M, et al: Circulating chromogranin A in the assessment of patients with neuroendocrine tumors. A single institution experience. Ann Oncol 2001;12(suppl 2):S73–S77.
68.
Oberg K, Skogseid B: The ultimate biochemical diagnosis of endocrine pancreatic tumors in MEN-1. J Intern Med 1998;243:471–476.
69.
Migliori M, Tomassetti P, Campana D, et al: A meal stimulation test in the diagnosis of pancreatic endocrine tumors in multiple endocrine neoplasia type 1. Endocrine 2002;17:229–232.
70.
Siddiqui MT, Gokaslan ST, Saboorian MH, Ashfaq R: Split sample comparison of ThinPrep and conventional smears in endoscopic retrograde cholangiopancreatography-guided pancreatic fine-needle aspirations. Diagn Cytopathol 2005;32:70–75.
71.
Calender A, Morrison C: The BT. Multiple Endocrine Neoplasia Type 1. Lyon, IARC, 2004.
72.
Kloeppel G, Anlauf M, Lüttges J: Klassifikation und Pathologie der neuroendokrinen Tumoren des Magen-Darm-Traktes und Pankreas. Onkologe 2004;10:570–579.
73.
Hellman P, Andersson M, Rastad J, et al: Surgical strategy for large or malignant endocrine pancreatic tumors. World J Surg 2000;24:1353–1360.
74.
Norton JA, Kivlen M, Li M, et al: Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg 2003;138:859–866.
75.
Evans DB, Skibber JM, Lee JE, et al: Nonfunctioning islet cell carcinoma of the pancreas. Surgery 1993;114:1175–1181; discussion 1181–1182.
76.
Lehnert H, Becker W, Dralle H, et al: Neuroendokrine Tumore des Gastrointestinaltrakts, ed 2. Stuttgart, Georg Thieme Verlag, 2003.
77.
Solorzano CC, Lee JE, Pisters PW, et al: Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001;130:1078–1085.
78.
Akerstrom G, Hessman O, Skogseid B: Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbecks Arch Surg 2002;386:558–569.
79.
Triponez F, Goudet P, Dosseh D, et al: Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 2006;30:654–662; discussion 663–664.
80.
Triponez F, Dosseh D, Goudet P, et al: Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg 2006;243:265–272.
81.
Balzano G, Zerbi A, Veronesi P, et al: Surgical treatment of benign and borderline neoplasms of the pancreatic body. Dig Surg 2003;20:506–510.
82.
Warshaw AL, Rattner DW, Fernandez-del Castillo C, Z’Graggen K: Middle segment pancreatectomy: a novel technique for conserving pancreatic tissue. Arch Surg 1998;133:327–331.
83.
Yamaguchi K, Yokohata K, Ohkido M, et al: Which is less invasive – distal pancreatectomy or segmental resection? Int Surg 2000;85:297–302.
84.
Phan GQ, Yeo CJ, Hruban RH, et al: Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg 1998;2:472–482.
85.
Que FG, Nagorney DM, Batts KP, et al: Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 1995;169:36–42; discussion 42–43.
86.
Creutzfeldt W, Bartsch HH, Jacubaschke U, Stockmann F: Treatment of gastrointestinal endocrine tumors with interferon-alpha and octreotide. Acta Oncol 1991;30:529–535.
87.
Skogseid B, Oberg K, Eriksson B, et al: Surgery for asymptomatic pancreatic lesion in multiple endocrine neoplasia type I. World J Surg 1996;20:872–876; discussion 877.
88.
Doherty GM, Olson JA, Frisella MM, et al: Lethality of multiple endocrine neoplasia type I. World J Surg 1998;22:581–586; discussion 586–587.
89.
Dean PG, van Heerden JA, Farley DR, et al: Are patients with multiple endocrine neoplasia type I prone to premature death? World J Surg 2000;24:1437–1441.
90.
Dralle H, Krohn SL, Karges W, et al: Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg 2004;28:1248–1260.
91.
Anlauf M, Schlenger R, Perren A, et al: Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol 2006;30:560–574.
92.
Kouvaraki MA, Greer M, Sharma S, et al: Indications for operative intervention in patients with asymptomatic primary hyperparathyroidism: practice patterns of endocrine surgery. Surgery 2006;139:527–534.
93.
Grama D, Eriksson B, Martensson H, et al: Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg 1992;16:632–639.
94.
Lowney JK, Frisella MM, Lairmore TC, Doherty GM: Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size. Surgery 1998;124:1043–1048; discussion 1048–1049.
95.
Thompson GB, van Heerden JA, Grant CS, et al: Islet cell carcinomas of the pancreas: a twenty-year experience. Surgery 1988;104:1011–1017.
96.
Pederzoli P, Falconi M, Bonora A, et al: Cytoreductive surgery in advanced endocrine tumors of the pancreas. Ital J Gastroenterol Hepatol 1999;31(suppl 2):S207–S212.
97.
Wiedenmann B, Jensen RT, Mignon M, et al: Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg 1998;22:309–318.
98.
Chamberlain RS, Canes D, Brown KT, et al: Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000;190:432–445.
99.
Chen H, Hardacre JM, Uzar A, et al: Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg 1998;187:88–92; discussion 92–93.
100.
Nave H, Mossinger E, Feist H, et al: Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery 2001;129:170–175.
101.
Sarmiento JM, Heywood G, Rubin J, et al: Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003;197:29–37.
102.
House MG, Cameron JL, Lillemoe KD, et al: Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg 2006;10:138–145.
103.
McEntee GP, Nagorney DM, Kvols LK, et al: Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990;108:1091–1096.
104.
Touzios JG, Kiely JM, Pitt SC, et al: Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005;241:776–783; discussion 783–785.
105.
Ahlman H, Wangberg B, Jansson S, et al: Interventional treatment of gastrointestinal neuroendocrine tumors. Digestion 2000;62(suppl 1):59–68.
106.
Sarmiento JM, Que FG: Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 2003;12:231–242.
107.
Andersen JR, Sorensen SM, Kruse A, et al: Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut 1989;30:1132–1135.
108.
Welvaart K: Operative bypass for incurable cancer of the head of the pancreas. Eur J Surg Oncol 1992;18:353–356.
109.
Zogakis TG, Norton JA: Palliative operations for patients with unresectable endocrine neoplasia. Surg Clin N Am 1995;75:525–538.
110.
Clouse ME, Perry L, Stuart K, Stokes KR: Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 1994;55(suppl 3):92–97.
111.
Diaco DS, Hajarizadeh H, Mueller CR, et al: Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization. Am J Surg 1995;169:523–528.
112.
Dominguez S, Denys A, Madeira I, et al: Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumors. Eur J Gastroenterol Hepatol 2000;12:151–1577.
113.
Eriksson BK, Larsson EG, Skogseid BM, et al: Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998;83:2293–2301.
114.
Falconi M, Bassi C, Bonora A, et al: Role of chemoembolization in synchronous liver metastases from pancreatic endocrine tumors. Dig Surg 1999;16:32–38.
115.
Fiorentini G, Rossi S, Bonechi F, et al: Intra-arterial hepatic chemoembolization in liver metastases from neuroendocrine tumors: a phase II study. J Chemother 2004;16:293–297.
116.
Gupta S, Johnson MM, Murthy R, et al: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005;104:1590–1602.
117.
Kress O, Wagner HJ, Wied M, et al: Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors: a retrospective single-center analysis. Digestion 2003;68:94–101.
118.
Loewe C, Schindl M, Cejna M, et al: Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. Am J Roentgenol 2003;180:1379–1384.
119.
Perry LJ, Stuart K, Stokes KR, Clouse ME: Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 1994;116:1111–1116; discussion 1116–1117.
120.
Roche A, Girish BV, de Baere T, et al: Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003;13:136–140.
121.
Ruszniewski P, Rougier P, Roche A, et al: Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors: a prospective phase II study in 24 patients. Cancer 1993;71:2624–2630.
122.
Therasse E, Breittmayer F, Roche A, et al: Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 1993;189:541–547.
123.
Yao KA, Talamonti MS, Nemcek A, et al: Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 2001;130:677–682; discussion 682–685.
124.
Proye C: Natural history of liver metastasis of gastroenteropancreatic neuroendocrine tumors: place for chemoembolization. World J Surg 2001;25:685–688.
125.
Hellman P, Ladjevardi S, Skogseid B, et al: Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 2002;26:1052–1056.
126.
Machi J, Uchida S, Sumida K, et al: Ultrasound-guided radiofrequency thermal ablation of liver tumors: percutaneous, laparoscopic, and open surgical approaches. J Gastrointest Surg 2001;5:477–489.
127.
Bilchik AJ, Rose DM, Allegra DP, et al: Radiofrequency ablation: a minimally invasive technique with multiple applications. Cancer J Sci Am 1999;5:356–361.
128.
Siperstein A, Garland A, Engle K, et al: Local recurrence after laparoscopic radiofrequency thermal ablation of hepatic tumors. Ann Surg Oncol 2000;7:106–113.
129.
Siperstein AE, Berber E: Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 2001;25:693–696.
130.
Siperstein AE, Rogers SJ, Hansen PD, Gitomirsky A: Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases. Surgery 1997;122:1147–1154; discussion 1154–1155.
131.
Berber E, Flesher N, Siperstein AE: Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 2002;26:985–990.
132.
Gillams A, Cassoni A, Conway G, Lees W: Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. Abdom Imaging 2005;30:435–441.
133.
Dhabuwala A, Lamerton P, Stubbs RS: Relationship of 99mtechnetium labelled macroaggregated albumin (99mTc-MAA) uptake by colorectal liver metastases to response following Selective Internal Radiation Therapy (SIRT). BMC Nucl Med 2005;5:7.
134.
Andrews JC, Walker SC, Ackermann RJ, et al: Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994;35:1637–1644.
135.
Anthuber M, Jauch KW, Briegel J, et al: Results of liver transplantation for gastroenteropancreatic tumor metastases. World J Surg 1996;20:73–76.
136.
Arnold JC, O’Grady JG, Bird GL, et al: Liver transplantation for primary and secondary hepatic apudomas. Br J Surg 1989;76:248–249.
137.
Bechstein WO, Neuhaus P: Liver transplantation for hepatic metastases of neuroendocrine tumors. Ann NY Acad Sci 1994;733:507–514.
138.
Cahlin C, Friman S, Ahlman H, et al: Liver transplantation for metastatic neuroendocrine tumor disease. Transplant Proc 2003;35:809–810.
139.
Lang H, Oldhafer KJ, Weimann A, et al: Liver transplantation for metastatic neuroendocrine tumors. Ann Surg 1997;225:347–354.
140.
Le Treut YP, Delpero JR, Dousset B, et al: Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann Surg 1997;225:355–364.
141.
Lehnert T: Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. Transplantation 1998;66:1307–1312.
142.
Olausson M, Friman S, Cahlin C, et al: Indications and results of liver transplantation in patients with neuroendocrine tumors. World J Surg 2002;26:998–1004.
143.
Rosenau J, Bahr MJ, von Wasielewski R, et al: Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors. Transplantation 2002;73:386–394.
144.
Pascher A, Klupp J, Neuhaus P: Endocrine tumors of the gastrointestinal tract. Transplantation in the management of metastatic endocrine tumors. Best Pract Res Clin Gastroenterol 2005;19:637–648.
145.
Ahlman H, Friman S, Cahlin C, et al: Liver transplantation for treatment of metastatic neuroendocrine tumors. Ann NY Acad Sci 2004;1014:265–269.
146.
Ringe B, Lorf T, Dopkens K, Canelo R: Treatment of hepatic metastases from gastroenteropancreatic neuroendocrine tumors: role of liver transplantation. World J Surg 2001;25:697–699.
147.
Panzuto F, Di Fonzo M, Iannicelli E, et al: Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol 2006;17:461–466.
148.
Arnold R, Trautmann ME, Creutzfeldt W, et al: Somatostatin analogue octreotide and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Gut 1996;38:430–438.
149.
Aparicio T, Ducreux M, Baudin E, et al: Antitumor activity of somatostatin analogues in progressive metastatic neuroendocrine tumors. Eur J Cancer 2001;37:1014–1019.
150.
Tomassetti P, Migliori M, Corinaldesi R, Gullo L: Treatment of gastroenteropancreatic neuroendocrine tumors with octreotide LAR. Aliment Pharmacol Ther 2000;14:557–560.
151.
O’Toole D, Ducreux M, Bommelaer G, et al: Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000;88:770–776.
152.
Saltz L, Trochanowski B, Buckley M, et al: Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993;72:244–248.
153.
Plockinger U, Dienemann D, Quabbe HJ: Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J Clin Endocrinol Metab 1990;71:1658–1562.
154.
Eriksson B, Oberg K, Alm G, et al: Treatment of malignant endocrine pancreatic tumors with human leukocyte interferon. Lancet 1986;2:1307–1309.
155.
Faiss S, Pape UF, Bohmig M, et al: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003;21:2689–2696.
156.
Arnold R, Rinke A, Klose KJ, et al: Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005;3:761–771.
157.
Moertel CG, Lefkopoulo M, Lipsitz S, et al: Streptozocin-doxorubicin, streptozotocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519–523.
158.
Ducreux M, Ruszniewski P, Chayvialle JA, et al: The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000;95:3276–3281.
159.
Fjallskog ML, Granberg DP, Welin SL, et al: Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92:1101–1107.
160.
Pavel ME, Baum U, Hahn EG, Hensen J: Doxorubicin and streptozotocin after failed biotherapy of neuroendocrine tumors. Int J Gastrointest Cancer 2005;35:179–185.
161.
Sun W, Lipsitz S, Catalano P, et al: Phase II/III study of doxorubicin with fluorouracil compared with streptozotocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005;23:4897–4904.
162.
Kouvaraki MA, Ajani JA, Hoff P, et al: Fluorouracil, doxorubicin, and streptozotocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762–4771.
163.
Ramanathan RK, Cnaan A, Hahn RG, et al: Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001;12:1139–1143.
164.
Fine R, Fogelman D, Schreibman SM: Effective treatment of neuroendocrine tumors with temozolomide and capecitabine. ASCO Proceedings, 2005, p 4216.
165.
Lankat-Buttgereit B, Horsch D, Barth P, et al: Effects of the tyrosine kinase inhibitor imatinib on neuroendocrine tumor cell growth. Digestion 2005;71:131–140.
166.
Kwekkeboom DJ, Bakker WH, Kam BL, et al: Treatment of patients with gastro-entero-pancreatic (GEP) tumors with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417–422.
167.
Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al: Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46(suppl 1):62S–66S.
168.
Nehar D, Lombard-Bohas C, Olivieri S, et al: Interest of Chromogranin A for diagnosis and follow-up of endocrine tumors. Clin Endocrinol (Oxf) 2004;60:644–652.
169.
di Bartolomeo M, Bajetta E, Buzzoni R, et al: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996;77:402–408.
170.
Arnold R, Benning R, Neuhaus C, et al: Gastroenteropancreatic endocrine tumors: effect of sandostatin on tumor growth. The German Sandostatin Study Group. Digestion 1993;54(suppl 1):72–75.
171.
Faiss S, Rath U, Mansmann U, et al: Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 1999;60:469–476.
© 2006 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the...
© 2006 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.